✦ LIBER ✦

Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase - 4 Inhibitors) for the Treatment of Type 2 Diabetes

✍ Scribed by Amir Hanna; Vincent Woo; Jean-François Yale; Elaine M. Cooke

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incretin-based treatment of type 2 diabe

✍ Carolyn F. Deacon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

The incretin system: glucagon-like pepti

✍ Daniel J Drucker; Michael A Nauck 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 320 KB

Novel therapeutics for type 2 diabetes:

✍ E.J. Verspohl 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 913 KB

Glucagon-like peptide 1 and inhibitors o

✍ Jens Juul Holst; Carolyn F Deacon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Glycaemic efficacy of glucagon-like pept

✍ C. F. Deacon; E. Mannucci; B. Ahrén 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Potential therapies mimicking the effect

✍ J. Rachman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB

Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase&#xa0;-&#xa0;4 Inhibitors) for the Treatment of Type 2 Diabetes